JP2003528918A5 - - Google Patents

Download PDF

Info

Publication number
JP2003528918A5
JP2003528918A5 JP2001572106A JP2001572106A JP2003528918A5 JP 2003528918 A5 JP2003528918 A5 JP 2003528918A5 JP 2001572106 A JP2001572106 A JP 2001572106A JP 2001572106 A JP2001572106 A JP 2001572106A JP 2003528918 A5 JP2003528918 A5 JP 2003528918A5
Authority
JP
Japan
Prior art keywords
dioxopiperidine
phthalimido
succimido
allyl
benzyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2001572106A
Other languages
English (en)
Other versions
JP2003528918A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2001/010581 external-priority patent/WO2001074362A1/en
Publication of JP2003528918A publication Critical patent/JP2003528918A/ja
Publication of JP2003528918A5 publication Critical patent/JP2003528918A5/ja
Pending legal-status Critical Current

Links

Description

【特許請求の範囲】
【請求項1】 下記式:
【化1】
Figure 2003528918
ただし、Rは、水素、1〜6個の炭素原子を有するアルキル、2〜6個の炭素原子を有するアルケニル、モルホルリノメチル、フェニル、またはベンジルであり、および
R’は、下記式:
【化2】
Figure 2003528918
である、
のアミドまたはイミド、および少なくとも一の製薬上許容できる担体、希釈剤または賦形剤を含む、プロスタグランジン生合成を抑制するための哺乳動物におけるシクロオキシゲナーゼ−2の活性の阻害に使用される薬剤組成物。
【請求項2】 該アミドまたはイミドは、1−アリル−3−フタルイミド−2,6−ジオキソピペリジン、1−エチル−3−フタルイミド−2,6−ジオキソピペリジン、1−フェニル−3−フタルイミド−2,6−ジオキソピペリジン、1−ベンジル−3−フタルイミド−2,6−ジオキソピペリジン、3−スクシミド−2,6−ジオキソピペリジン、及び1−アリル−3−スクシミド−2,6−ジオキソピペリジンからなる群より選択される、請求項1に記載の薬剤組成物。
JP2001572106A 2000-03-31 2001-03-30 シクロオキシゲナーゼ−2活性の阻害 Pending JP2003528918A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US19398100P 2000-03-31 2000-03-31
US09/193,981 2000-03-31
PCT/US2001/010581 WO2001074362A1 (en) 2000-03-31 2001-03-30 Inhibition of cyclooxygenase-2 activity

Publications (2)

Publication Number Publication Date
JP2003528918A JP2003528918A (ja) 2003-09-30
JP2003528918A5 true JP2003528918A5 (ja) 2008-05-29

Family

ID=22715841

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2001572106A Pending JP2003528918A (ja) 2000-03-31 2001-03-30 シクロオキシゲナーゼ−2活性の阻害

Country Status (11)

Country Link
US (4) US20020022627A1 (ja)
EP (1) EP1272189A4 (ja)
JP (1) JP2003528918A (ja)
KR (1) KR20030003708A (ja)
CN (1) CN1420776A (ja)
AU (1) AU2001249755A1 (ja)
CA (1) CA2404152C (ja)
MX (1) MXPA02009665A (ja)
NO (1) NO20024627L (ja)
NZ (1) NZ521937A (ja)
WO (1) WO2001074362A1 (ja)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5635517B1 (en) * 1996-07-24 1999-06-29 Celgene Corp Method of reducing TNFalpha levels with amino substituted 2-(2,6-dioxopiperidin-3-YL)-1-oxo-and 1,3-dioxoisoindolines
HU228769B1 (en) * 1996-07-24 2013-05-28 Celgene Corp Substituted 2(2,6-dioxopiperidin-3-yl)phthalimides and -1-oxoisoindolines and their use for production of pharmaceutical compositions for mammals to reduce the level of tnf-alpha
US20030013739A1 (en) * 1998-12-23 2003-01-16 Pharmacia Corporation Methods of using a combination of cyclooxygenase-2 selective inhibitors and thalidomide for the treatment of neoplasia
US7629360B2 (en) * 1999-05-07 2009-12-08 Celgene Corporation Methods for the treatment of cachexia and graft v. host disease
US6458810B1 (en) 2000-11-14 2002-10-01 George Muller Pharmaceutically active isoindoline derivatives
AU2002253795B2 (en) * 2000-11-30 2007-02-01 The Children's Medical Center Corporation Synthesis of 4-Amino-Thalidomide enantiomers
WO2002068414A2 (en) * 2001-02-27 2002-09-06 The Governement Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services Analogs of thalidomide as potential angiogenesis inhibitors
USRE48890E1 (en) 2002-05-17 2022-01-11 Celgene Corporation Methods for treating multiple myeloma with 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione after stem cell transplantation
US7393862B2 (en) 2002-05-17 2008-07-01 Celgene Corporation Method using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for treatment of certain leukemias
US7323479B2 (en) * 2002-05-17 2008-01-29 Celgene Corporation Methods for treatment and management of brain cancer using 1-oxo-2-(2,6-dioxopiperidin-3-yl)-4-methylisoindoline
CA2486141A1 (en) * 2002-05-17 2003-11-27 Celgene Corporation Methods and compositions using selective cytokine inhibitory drugs for treatment and management of cancers and other diseases
US7968569B2 (en) 2002-05-17 2011-06-28 Celgene Corporation Methods for treatment of multiple myeloma using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione
US20100129363A1 (en) * 2002-05-17 2010-05-27 Zeldis Jerome B Methods and compositions using pde4 inhibitors for the treatment and management of cancers
WO2004034962A2 (en) * 2002-10-15 2004-04-29 Celgene Corporation Selective cytokine inhibitory drugs for treating myelodysplastic syndrome
US8404717B2 (en) * 2002-10-15 2013-03-26 Celgene Corporation Methods of treating myelodysplastic syndromes using lenalidomide
US11116782B2 (en) 2002-10-15 2021-09-14 Celgene Corporation Methods of treating myelodysplastic syndromes with a combination therapy using lenalidomide and azacitidine
US7189740B2 (en) 2002-10-15 2007-03-13 Celgene Corporation Methods of using 3-(4-amino-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myelodysplastic syndromes
US8404716B2 (en) 2002-10-15 2013-03-26 Celgene Corporation Methods of treating myelodysplastic syndromes with a combination therapy using lenalidomide and azacitidine
US20050203142A1 (en) * 2002-10-24 2005-09-15 Zeldis Jerome B. Methods of using and compositions comprising immunomodulatory compounds for treatment, modification and management of pain
US20040091455A1 (en) * 2002-10-31 2004-05-13 Zeldis Jerome B. Methods of using and compositions comprising immunomodulatory compounds for treatment and management of macular degeneration
US8034831B2 (en) * 2002-11-06 2011-10-11 Celgene Corporation Methods for the treatment and management of myeloproliferative diseases using 4-(amino)-2-(2,6-Dioxo(3-piperidyl)-isoindoline-1,3-dione in combination with other therapies
US7563810B2 (en) * 2002-11-06 2009-07-21 Celgene Corporation Methods of using 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myeloproliferative diseases
US7230012B2 (en) * 2002-11-14 2007-06-12 Celgene Corporation Pharmaceutical compositions and dosage forms of thalidomide
US9006267B2 (en) 2002-11-14 2015-04-14 Celgene Corporation Pharmaceutical compositions and dosage forms of thalidomide
UA83504C2 (en) 2003-09-04 2008-07-25 Селджин Корпорейшн Polymorphic forms of 3-(4-amino-1-oxo-1,3 dihydro-isoindol-2-yl)-piperidine-2,6-dione
US20080027113A1 (en) * 2003-09-23 2008-01-31 Zeldis Jerome B Methods of Using and Compositions Comprising Immunomodulatory Compounds for Treatment and Management of Macular Degeneration
US7612096B2 (en) * 2003-10-23 2009-11-03 Celgene Corporation Methods for treatment, modification and management of radiculopathy using 1-oxo-2-(2,6-dioxopiperidin-3yl)-4-aminoisoindoline
AP2006003637A0 (en) * 2003-11-06 2006-06-30 Celgene Corp Methods and compositions using thalidomide for thetreatment and management of cancers and other diseases
US20050100529A1 (en) * 2003-11-06 2005-05-12 Zeldis Jerome B. Methods of using and compositions comprising immunomodulatory compounds for the treatment and management of asbestos-related diseases and disorders
US20050143344A1 (en) * 2003-12-30 2005-06-30 Zeldis Jerome B. Methods and compositions using immunomodulatory compounds for the treatment and management of central nervous system disorders or diseases
EP2505200A1 (en) * 2004-03-22 2012-10-03 Celgene Corporation Methods of using and compositions comprising immunomodulatory compounds for the treatment and management of scleroderma
US20050222209A1 (en) * 2004-04-01 2005-10-06 Zeldis Jerome B Methods and compositions for the treatment, prevention or management of dysfunctional sleep and dysfunctional sleep associated with disease
WO2005110408A1 (en) * 2004-04-14 2005-11-24 Celgene Corporation Methods of using and compositions comprising immunomodulatory compounds for the treatment and management of myelodysplastic syndromes
BRPI0418743A (pt) * 2004-04-14 2007-09-18 Celgene Corp métodos de tratamento, prevenção ou controle de uma sìndrome mielodisplásica, de redução ou evitação de um efeito adverso associado com a administração de um segundo ingrediente ativo em um paciente sofrendo de uma sìndrome mielodisplásica, composição farmacêutica, forma de dosagem unitária única, e, kit
US20050239842A1 (en) * 2004-04-23 2005-10-27 Zeldis Jerome B Methods of using and compositions comprising immunomodulatory compounds for the treatment and management of pulmonary hypertension
WO2006058008A1 (en) * 2004-11-23 2006-06-01 Celgene Corporation Methods and compositions using immunomodulatory compounds for treatment and management of central nervous system injury
US20060270707A1 (en) * 2005-05-24 2006-11-30 Zeldis Jerome B Methods and compositions using 4-[(cyclopropanecarbonylamino)methyl]-2-(2,6-dioxopiperidin-3-yl)isoindole-1,3-dione for the treatment or prevention of cutaneous lupus
US20080138295A1 (en) * 2005-09-12 2008-06-12 Celgene Coporation Bechet's disease using cyclopropyl-N-carboxamide
US20070155791A1 (en) * 2005-12-29 2007-07-05 Zeldis Jerome B Methods for treating cutaneous lupus using aminoisoindoline compounds
CL2007002218A1 (es) * 2006-08-03 2008-03-14 Celgene Corp Soc Organizada Ba Uso de 3-(4-amino-1-oxo-1,3-dihidro-isoindol-2-il)-piperidina 2,6-diona para la preparacion de un medicamento util para el tratamiento de linfoma de celula de capa.
WO2009020590A1 (en) * 2007-08-07 2009-02-12 Celgene Corporation Methods for treating lymphomas in certain patient populations and screening patients for said therapy
AU2015305449B2 (en) 2014-08-22 2021-05-06 Celgene Corporation Methods of treating multiple myeloma with immunomodulatory compounds in combination with antibodies
CN106137986B (zh) * 2015-03-09 2019-04-16 常州制药厂有限公司 一种沙利度胺片及其制备方法
JP2018527302A (ja) 2015-06-26 2018-09-20 セルジーン コーポレイション 免疫調節化合物を用いたカポジ肉腫またはkshv誘発性リンパ腫の治療方法、及びバイオマーカーの使用

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2830991A (en) * 1954-05-17 1958-04-15 Gruenenthal Chemie Products of the amino-piperidine-2-6-dione series
US3536809A (en) * 1969-02-17 1970-10-27 Alza Corp Medication method
US3598123A (en) * 1969-04-01 1971-08-10 Alza Corp Bandage for administering drugs
US3845770A (en) * 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3916899A (en) * 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
US4008719A (en) * 1976-02-02 1977-02-22 Alza Corporation Osmotic system having laminar arrangement for programming delivery of active agent
IE58110B1 (en) * 1984-10-30 1993-07-14 Elan Corp Plc Controlled release powder and process for its preparation
US5391485A (en) * 1985-08-06 1995-02-21 Immunex Corporation DNAs encoding analog GM-CSF molecules displaying resistance to proteases which cleave at adjacent dibasic residues
JPS63500636A (ja) * 1985-08-23 1988-03-10 麒麟麦酒株式会社 多分化能性顆粒球コロニー刺激因子をコードするdna
US4810643A (en) * 1985-08-23 1989-03-07 Kirin- Amgen Inc. Production of pluripotent granulocyte colony-stimulating factor
US5073543A (en) * 1988-07-21 1991-12-17 G. D. Searle & Co. Controlled release formulations of trophic factors in ganglioside-lipsome vehicle
IT1229203B (it) * 1989-03-22 1991-07-25 Bioresearch Spa Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative.
US5120548A (en) * 1989-11-07 1992-06-09 Merck & Co., Inc. Swelling modulated polymeric drug delivery device
KR0166088B1 (ko) * 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
US5733566A (en) * 1990-05-15 1998-03-31 Alkermes Controlled Therapeutics Inc. Ii Controlled release of antiparasitic agents in animals
AU1531492A (en) * 1991-02-14 1992-09-15 Rockefeller University, The Method for controlling abnormal concentration tnf alpha in human tissues
US5580578A (en) * 1992-01-27 1996-12-03 Euro-Celtique, S.A. Controlled release formulations coated with aqueous dispersions of acrylic polymers
US5360352A (en) * 1992-12-24 1994-11-01 The Whitaker Corporation Wire retainer for current mode coupler
US5591767A (en) * 1993-01-25 1997-01-07 Pharmetrix Corporation Liquid reservoir transdermal patch for the administration of ketorolac
US6114355A (en) * 1993-03-01 2000-09-05 D'amato; Robert Methods and compositions for inhibition of angiogenesis
US5629327A (en) * 1993-03-01 1997-05-13 Childrens Hospital Medical Center Corp. Methods and compositions for inhibition of angiogenesis
US5698579A (en) * 1993-07-02 1997-12-16 Celgene Corporation Cyclic amides
IT1270594B (it) * 1994-07-07 1997-05-07 Recordati Chem Pharm Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida
US5731325A (en) * 1995-06-06 1998-03-24 Andrulis Pharmaceuticals Corp. Treatment of melanomas with thalidomide alone or in combination with other anti-melanoma agents
US5635517B1 (en) * 1996-07-24 1999-06-29 Celgene Corp Method of reducing TNFalpha levels with amino substituted 2-(2,6-dioxopiperidin-3-YL)-1-oxo-and 1,3-dioxoisoindolines
US5798368A (en) * 1996-08-22 1998-08-25 Celgene Corporation Tetrasubstituted 2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolines and method of reducing TNFα levels
EP1361210B1 (en) * 1996-08-12 2008-12-24 Celgene Corporation Novel immunotherapeutic agents and their use in the reduction of cytokine levels
US5955476A (en) * 1997-11-18 1999-09-21 Celgene Corporation Substituted 2-(2,6-dioxo-3-fluoropiperidin-3-yl)-isoindolines and method of reducing inflammatory cytokine levels
US5874448A (en) * 1997-11-18 1999-02-23 Celgene Corporation Substituted 2-(2,6 dioxo-3-fluoropiperidin-3-yl)-isoindolines and method of reducing TNFα levels
US6020358A (en) * 1998-10-30 2000-02-01 Celgene Corporation Substituted phenethylsulfones and method of reducing TNFα levels
US6590243B2 (en) * 1999-04-28 2003-07-08 Sharp Laboratories Of America, Inc. Ferroelastic lead germanate thin film and deposition method

Similar Documents

Publication Publication Date Title
JP2003528918A5 (ja)
JP2002508362A5 (ja) 1−置換−1−アミノメチル−シクロアルカン誘導体(=ガバペンチン類縁体)
CA2530006A1 (en) Phenylcarboxylate beta-secretase inhibitors for the treatment of alzheimer's disease
EP1741712A3 (en) Nebivolol and its pharmaceutically acceptable salts, process for preparation and pharmaceutical compositions of Nebivolol
JP2002540208A5 (ja)
RS20110564A2 (en) ONE-DAY OXYCODON FORMULATIONS
SE0300010D0 (sv) Novel Compounds
MXPA05008172A (es) Derivados de malonamida como inhibidores gamma-secretasa.
JP2002502874A5 (ja)
JP2004529078A5 (ja)
JP2003531118A5 (ja)
JP2008546770A5 (ja)
JP2002527474A5 (ja) 躁病および双極性障害の治療のための医薬
HUP0203376A2 (hu) Ciklooxigenáz-2 inhibitor hatású 5-aril-1h-1,2,4-triazol-származékok és ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk
GEP20115211B (en) Terphenyl derivatives for treatment of alzheimer' s disease
TNSN07145A1 (fr) Derives de 2-amido-4-phenylthiazole, leur preparation et leur application en therapeutique
IL184116A0 (en) Use of thiazolidinone derivatives as antiangiogenic agents
JP2002520286A5 (ja)
JP2002506864A5 (ja)
MY140410A (en) Tetrazole derivatives and methods of treatment of metabolic-related disorders thereof
AR048948A1 (es) Una composicion farmaceutica antimicobacteriana
JP2003512494A5 (ja)
JP2001519413A5 (ja)
JP2002544191A5 (ja)
JP2005534668A5 (ja)